Full metadata record
DC FieldValueLanguage
dc.creatorBono, J. (Johann) de-
dc.creatorLin, C.C. (Chia-Chi)-
dc.creatorChen, L.T. (Li-Tzung)-
dc.creatorCorral, J. (Jesús)-
dc.creatorMichalarea, V. (Vasiliki)-
dc.creatorRihawi, K. (Karim)-
dc.creatorOng, M. (Michael)-
dc.creatorLee, J.G. (Jih-Hsiang)-
dc.creatorHsu, C.H. (Chih-Hung)-
dc.creatorChih-Hsin-Yang, J. (James)-
dc.creatorShiah, H.S. (Her-Shyong)-
dc.creatorYen, C.J. (Chia-Jui)-
dc.creatorAnthoney, A. (Alan)-
dc.creatorJove, M. (Maria)-
dc.creatorBuschke, S. (Susanne)-
dc.creatorFuertig, R. (René)-
dc.creatorSchmid, U. (Ulrike)-
dc.creatorGoeldner, R.G. (Rainer-Georg)-
dc.creatorStrelkowa, N. (Natalja)-
dc.creatorHuang, D.C.L. (Dennis Chin-Lun)-
dc.creatorBogenrieder, T. (Thomas)-
dc.creatorTwelves, C. (Chris)-
dc.creatorCheng, A.L. (Ann-Lii)-
dc.date.accessioned2023-09-21T12:34:25Z-
dc.date.available2023-09-21T12:34:25Z-
dc.date.issued2020-
dc.identifier.citationBono, J. (Johann) de; Lin, C.C. (Chia-Chi); Chen, L.T. (Li-Tzung); et al. "Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours". British journal of cancer. 122 (9), 2020, 1324 - 1332es
dc.identifier.issn0007-0920-
dc.identifier.urihttps://hdl.handle.net/10171/67298-
dc.description.abstractBACKGROUND: Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD), safety, pharmacokinetics, pharmacodynamics, and activity of xentuzumab in advanced/metastatic solid cancers. METHODS: These phase 1, open-label trials comprised dose-finding (part I; 3 + 3 design) and expansion cohorts (part II; selected tumours; RBD [weekly dosing]). Primary endpoints were MTD/RBD. RESULTS: Study 1280.1 involved 61 patients (part I: xentuzumab 10–1800 mg weekly, n = 48; part II: 1000 mg weekly, n = 13); study 1280.2, 64 patients (part I: 10–3600 mg three-weekly, n = 33; part II: 1000 mg weekly, n = 31). One dose-limiting toxicity occurred; the MTD was not reached for either schedule. Adverse events were generally grade 1/2, mostly gastrointestinal. Xentuzumab showed dose-proportional pharmacokinetics. Total plasma IGF-1 increased dose dependently, plateauing at ~1000 mg/week; at ≥450 mg/week, IGF bioactivity was almost undetectable. Two partial responses occurred (poorly differentiated nasopharyngeal carcinoma and peripheral primitive neuroectodermal tumour). Integration of biomarker and response data by Bayesian Logistic Regression Modeling (BLRM) confirmed the RBD. CONCLUSIONS: Xentuzumab was well tolerated; MTD was not reached. RBD was 1000 mg weekly, confirmed by BLRM. Xentuzumab showed preliminary anti-tumour activity.es_ES
dc.description.sponsorshipThe studies were supported by Boehringer Ingelheim. We received funding from ECMC and BRC grants to The Institute of Cancer Research and Royal Marsden. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Fiona Scott, of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this article.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectXentuzumabes_ES
dc.subjectInsulines_ES
dc.subjectBiological dosees_ES
dc.titleTwo first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumourses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.es_ES
dc.identifier.doi10.1038/s41416-020-0774-1-
dadun.citation.endingPage1332es_ES
dadun.citation.number9es_ES
dadun.citation.publicationNameBritish journal of canceres_ES
dadun.citation.startingPage1324es_ES
dadun.citation.volume122es_ES
dc.identifier.pmid32161368-

Files in This Item:
Thumbnail
File
s41416-020-0774-1.pdf
Description
Size
697.8 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.